Clinical Trial Detail

NCT ID NCT02521870
Title A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dynavax Technologies Corporation
Indications

melanoma

Therapies

Pembrolizumab

SD-101

Age Groups: adult

No variant requirements are available.